Ovid Therapeutics financials
$2.54+3.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $566.0K | $392.0K | $1.5M | $208.4M | $12.6M | — | — | — |
| Gross profit | $7.3M | $566.0K | $392.0K | $1.5M | $208.4M | $12.6M | — | — | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating income | -$42.4M | -$61.9M | -$59.3M | -$55.5M | $124.2M | -$81.0M | -$60.5M | -$52.9M | -$65.0M |
| Net income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | $119.8M | -$81.0M | -$60.5M | -$52.0M | -$64.8M |
| Net margin | −240.1% | −4670.1% | −13351.8% | −3604.7% | 57.5% | −642.3% | — | — | — |
| Diluted EPS | $-0.23 | $-0.37 | $-0.73 | $-0.77 | $1.76 | $-1.39 | $-1.54 | $-2.11 | $-3.35 |
| EBITDA | -$42.2M | -$61.3M | -$58.7M | -$54.2M | $124.4M | -$80.7M | -$60.2M | -$52.8M | -$64.9M |
| Operating cash flow | -$38.3M | -$56.0M | -$45.8M | -$55.2M | $118.6M | -$51.6M | -$51.1M | -$45.5M | -$31.4M |
| Free cash flow | -$38.3M | -$56.0M | -$45.8M | -$56.5M | $118.4M | -$51.7M | -$51.1M | -$45.6M | -$31.5M |
| Diluted shares | 73.7M | 70.9M | 70.6M | 70.4M | 68.1M | 58.5M | 39.2M | 24.6M | 19.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.2M | $26.3M | $27.0M | $44.9M | $187.8M | $72.0M |
| Short-term investments | $56.5M | $26.8M | $78.8M | $84.1M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $150.9M | $92.2M | $144.0M | $155.3M | $194.5M | $75.9M |
| Total liabilities | $20.3M | $23.9M | $56.2M | $23.0M | $14.8M | $32.3M |
| Shareholders' equity | $130.7M | $68.2M | $87.8M | $132.3M | $179.7M | $43.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology